253 related articles for article (PubMed ID: 17968022)
1. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract][Full Text] [Related]
2. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
3. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
Skowronska A; Austen B; Powell JE; Weston V; Oscier DG; Dyer MJ; Matutes E; Pratt G; Fegan C; Moss P; Taylor MA; Stankovic T
Haematologica; 2012 Jan; 97(1):142-6. PubMed ID: 21933854
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
[TBL] [Abstract][Full Text] [Related]
5. Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
Britt-Compton B; Lin TT; Ahmed G; Weston V; Jones RE; Fegan C; Oscier DG; Stankovic T; Pepper C; Baird DM
Leukemia; 2012 Apr; 26(4):826-30. PubMed ID: 21986843
[No Abstract] [Full Text] [Related]
6. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
[TBL] [Abstract][Full Text] [Related]
7. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.
Ouillette P; Li J; Shaknovich R; Li Y; Melnick A; Shedden K; Malek SN
Genes Chromosomes Cancer; 2012 Dec; 51(12):1125-32. PubMed ID: 22952040
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
[TBL] [Abstract][Full Text] [Related]
9. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
[TBL] [Abstract][Full Text] [Related]
10. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Rose-Zerilli MJ; Forster J; Parker H; Parker A; Rodríguez AE; Chaplin T; Gardiner A; Steele AJ; Collins A; Young BD; Skowronska A; Catovsky D; Stankovic T; Oscier DG; Strefford JC
Haematologica; 2014 Apr; 99(4):736-42. PubMed ID: 24584352
[TBL] [Abstract][Full Text] [Related]
11. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
Guarini A; Marinelli M; Tavolaro S; Bellacchio E; Magliozzi M; Chiaretti S; De Propris MS; Peragine N; Santangelo S; Paoloni F; Nanni M; Del Giudice I; Mauro FR; Torrente I; Foà R
Haematologica; 2012 Jan; 97(1):47-55. PubMed ID: 21993670
[TBL] [Abstract][Full Text] [Related]
12. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
[TBL] [Abstract][Full Text] [Related]
13. A unique lethal blastoid transformation of B-cell chronic lymphocytic leukemia carrying ATM/11q deletion and trisomy 12.
Lu Y; Huang Q
Leuk Res; 2009 Aug; 33(8):e124-6. PubMed ID: 19269030
[No Abstract] [Full Text] [Related]
14. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
[TBL] [Abstract][Full Text] [Related]
15. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.
Stankovic T; Skowronska A
Leuk Lymphoma; 2014 Jun; 55(6):1227-39. PubMed ID: 23906020
[TBL] [Abstract][Full Text] [Related]
16. [Gene atm and chronic lymphocytic leukemia - review].
Zhu DX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1242-6. PubMed ID: 18928637
[TBL] [Abstract][Full Text] [Related]
17. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
Joshi AD; Dickinson JD; Hegde GV; Sanger WG; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Cancer Genet Cytogenet; 2007 Jan; 172(2):120-6. PubMed ID: 17213020
[TBL] [Abstract][Full Text] [Related]
18. Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
Lozano-Santos C; García-Vela JA; Pérez-Sanz N; Nova-Gurumeta S; Fernandez-Cuevas B; Gomez-Lozano N; Sánchez-Beato M; Sanchez-Godoy P; Bueno JL; Garcia-Marco JA
Leuk Lymphoma; 2017 Apr; 58(4):859-865. PubMed ID: 27499002
[TBL] [Abstract][Full Text] [Related]
19. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition.
Quijada-Álamo M; Hernández-Sánchez M; Alonso-Pérez V; Rodríguez-Vicente AE; García-Tuñón I; Martín-Izquierdo M; Hernández-Sánchez JM; Herrero AB; Bastida JM; San Segundo L; Gruber M; García JL; Yin S; Ten Hacken E; Benito R; Ordóñez JL; Wu CJ; Hernández-Rivas JM
Leukemia; 2020 Jun; 34(6):1599-1612. PubMed ID: 31974435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
